10th April 2024
Medherant’s testosterone TEPI Patch has been well-tolerated and has demonstrated excellent wearability.
General News
25th March 2024
Coventry, UK (25 March 2024): Medherant Limited (“Medherant”) announces that it has entered into a Development Collaboration Agreement with Bayer for the development of a transdermal patch product for delivery of an a
General News
18th October 2023
Did you know that peri-menopause and menopause affects over 13 million women in the UK?
General News
13th October 2023
The first group of volunteers has been dosed and further groups will participate in the study over the coming months.
General News
2nd October 2023
The study will be conducted by Hammersmith Medicines Research (HMR; London) and enrol up to 24 women to investigate the safety, tolerability and pharmacokinetics of testosterone delivered from Medherant TEPI Patch whe
General News
11th September 2023
11 September 2023 (Coventry, UK). Medherant announces that Dr Karolina Afors BSC MBBS MRCOG has joined the company in the newly-created role of Medical Director to lead the clinical development of the
General News
5th April 2023
3 April 2023. Medherant (Coventry, UK) announces that it has raised £2.9m of new funding from investors in a financing round led by Mercia Asset Management.
Press Releases
4th May 2020
Cambridge & Coventry, UK – 5 May 2020 – Cycle Pharmaceuticals Ltd (Cycle) and Medherant Ltd (Medherant) are pleased to announce that they have signed an agreement to develop and commercialize mult
Press Releases
Innovation 50 Medherant
23rd September 2019
Medherant Limited (“Medherant”), the clinical-stage company developing innovative products for pain and CNS diseases using a unique transdermal delivery technology, TEPI Patch
John Burt
25th June 2019
Coventry, UK, 25th June 2019 / Medherant Limited (“Medherant”), the clinical-stage company developing innovative products for pain and CNS diseases using a u
Press Releases